Episode # 3 • 17 Jan 2025
Molecular-Driven Therapies in Colorectal Cancer
Which molecular alterations in colorectal cancer now change treatment and how quickly do you need the results to make the right call? On this episode of BackTable Tumor Board, Dr. Jun Gong interviews Dr. Ibrahim Sahin and Dr. Sandra Algaze about the latest advances in molecular-driven therapy across adjuvant and metastatic settings. They cover aspirin in PI3K-altered disease, the shift toward early next-generation sequencing, and the operational realities of systematic profiling at diagnosis.
Timestamps
00:00 - Introduction
07:50 - BREAKWATER and First-Line BRAF Therapy
13:00 - Biomarker Turnaround and Systematic Profiling
17:58 - MSI-High Disease and Immunotherapy Trials
21:54 - Anti-PD-1 vs Anti-PD-L1 in CRC
25:17 - Doublet vs Single-Agent Immunotherapy
27:41 - KRYSTAL-10 and KRAS G12C Inhibition
33:34 - Anti-EGFR Sequencing and CR-SEQUENCE
38:47 - New Targets and Emerging Therapies
43:02 - Closing Remarks
Resources
You may also like
More about this episode
The discussion moves from first-line BRAF and MSI-high options to anti-EGFR sequencing, ctDNA hyperselection, and the nuances of chemotherapy backbone choice. Drs. Sahin and Algaze review new trial data including BREAKWATER, KEYNOTE-177, CheckMate 8HW, KRYSTAL-10, and CR-SEQUENCE, highlight the promise and pitfalls of targeted strategies, and close with a look at emerging therapies and the multidisciplinary teamwork needed to match biology to treatment.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.